title: Response to: 'Monocyte type I interferon signature in antiphospholipid syndrome is related to pro-inflammatory monocyte subsets, hydroxychloroquine and statin use' by van den Hoogen et al.
authors: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
authors: Srilakshmi
authors: S
authors: Yalavarthi
authors: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
authors: Robert C
authors: RC
authors: Grenn
authors: Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
authors: Jason S
authors: JS
authors: Knight
mesh_terms: D017152:Antibodies, Antiphospholipid; D016736:Antiphospholipid Syndrome; D006801:Humans; D006886:Hydroxychloroquine; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007370:Interferon Type I; D009000:Monocytes
chemical_list: D017152:Antibodies, Antiphospholipid; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007370:Interferon Type I; D006886:Hydroxychloroquine
keywords: Antiphospholipid Syndrome; Disease Activity; Treatment